Literature DB >> 9887244

Missed opportunities for cervical cancer screening of HMO members developing invasive cervical cancer (ICC).

W Kinney1, H Y Sung, K A Kearney, M Miller, G Sawaya, R A Hiatt.   

Abstract

OBJECTIVE: To identify potential missed opportunities and to suggest interventions for cervical cancer screening in members of a prepaid health plan by examining the membership histories and medical records of women who had no Pap smear performed in the 3 years prior to the diagnosis of ICC.
METHODS: Medical records of all 642 members of a prepaid health plan developing ICC during the period from 1988 to 1994 were reviewed and details of patient interaction with the health care system were abstracted. Assessment of screening history and history of clinic visits was limited to the period 36 months prior to diagnosis, but excluded the last 6 months prior to diagnosis, so as to avoid including smears or visits which were part of the evaluation that led to the recognition of ICC.
RESULTS: Of women developing ICC, 384/642 (60%) had not had a smear in the period from 36 months to 6 months preceding the diagnosis. Of these 384 unscreened women, 241 (63%) had been insured by our HMO for at least 30 of the 36 months prior to diagnosis. Contact with the medical system in one of the primary care outpatient clinics was documented in 180/241 (75%) of these long-standing members during the specified period. Considering only Internal Medicine and Family Practice clinic visits, 169/241 (70%) had been seen at least once and 101/241 (42%) had been seen 3 or more times.
CONCLUSION: Most long-standing HMO members developing ICC without benefit of recent Pap smear screening were seen in primary care outpatient clinics in the 3 years preceding their diagnosis. Copyright 1998 Academic Press.

Entities:  

Mesh:

Year:  1998        PMID: 9887244     DOI: 10.1006/gyno.1998.5135

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  13 in total

Review 1.  How can we develop a cost-effective quality cervical screening programme?

Authors:  Sue Wilson; Helen Lester
Journal:  Br J Gen Pract       Date:  2002-06       Impact factor: 5.386

2.  Opting out of cervical cancer screening: physicians who do not perform pap tests.

Authors:  Crystale Purvis Cooper; Mona Saraiya
Journal:  Am J Prev Med       Date:  2014-06-18       Impact factor: 5.043

3.  Vaginal self sampling versus physician cervical sampling for HPV among younger and older women.

Authors:  T Karwalajtys; M Howard; J W Sellors; J Kaczorowski
Journal:  Sex Transm Infect       Date:  2006-08       Impact factor: 3.519

4.  Application of the Carolina Framework for Cervical Cancer Prevention.

Authors:  Jennifer L Moss; Schatzi H McCarthy; Melissa B Gilkey; Noel T Brewer
Journal:  Gynecol Oncol       Date:  2013-12-10       Impact factor: 5.482

5.  Reactions of women underscreened for cervical cancer who received unsolicited human papillomavirus self-sampling kits.

Authors:  Colin Malone; Jasmin A Tiro; Diana Sm Buist; Tara Beatty; John Lin; Kilian Kimbel; Hongyuan Gao; Chris Thayer; Diana L Miglioretti; Rachel L Winer
Journal:  J Med Screen       Date:  2019-11-20       Impact factor: 2.136

6.  Cost-effectiveness studies of HPV self-sampling: A systematic review.

Authors:  Colin Malone; Ruanne V Barnabas; Diana S M Buist; Jasmin A Tiro; Rachel L Winer
Journal:  Prev Med       Date:  2020-01-03       Impact factor: 4.018

7.  Recommendations for a national agenda to substantially reduce cervical cancer.

Authors:  Jennifer S Smith; Noel T Brewer; Debbie Saslow; Kenneth Alexander; Mildred R Chernofsky; Richard Crosby; Libby Derting; Leah Devlin; Charles J Dunton; Jeffrey Engle; Maria Fernandez; Mona Fouad; Warner Huh; Walter Kinney; Jennifer Pierce; Elena Rios; Mitchel C Rothholz; Judith C Shlay; Rivienne Shedd-Steele; Sally W Vernon; Joan Walker; Theresa Wynn; Gregory D Zimet; Baretta R Casey
Journal:  Cancer Causes Control       Date:  2013-07-05       Impact factor: 2.506

8.  Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system.

Authors:  Rachel L Winer; Jasmin A Tiro; Diana L Miglioretti; Chris Thayer; Tara Beatty; John Lin; Hongyuan Gao; Kilian Kimbel; Diana S M Buist
Journal:  Contemp Clin Trials       Date:  2017-11-04       Impact factor: 2.226

9.  Cervical Cancer Burden and Opportunities for Prevention in a Safety-Net Healthcare System.

Authors:  Sandi L Pruitt; Claudia L Werner; Eric K Borton; Joanne M Sanders; Bijal A Balasubramanian; Arti Barnes; Andrea C Betts; Celette Sugg Skinner; Jasmin A Tiro
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-09-05       Impact factor: 4.254

10.  Out of reach? Correlates of cervical cancer underscreening in women with varying levels of healthcare interactions in a United States integrated delivery system.

Authors:  Colin Malone; Diana S M Buist; Jasmin Tiro; William Barlow; Hongyuan Gao; John Lin; Rachel L Winer
Journal:  Prev Med       Date:  2020-12-31       Impact factor: 4.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.